← Browse by Condition
Medical Condition
egfr positive non small cell lung cancer
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT07322783 Phase 2
Recruiting
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
Enrollment
60 pts
Location
China
Sponsor
Qingdao Central Hospital
NCT05037331
Recruiting
Osimertinib for Advanced EGFR-positive NSCLC Patients
Enrollment
58 pts
Location
Singapore
Sponsor
National University Hospital, ...